Dawnzera (donidalorsen), an injection therapy used to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), has been approved in the European Union as a preventive treatment for HAE patients 12 and older. That decision, by the European Commission, comes shortly after the therapy was…
News
People with hereditary angioedema (HAE) began experiencing symptom relief from swelling attacks of the larynx (voice box) or abdomen in less than two hours after taking oral Ekterly (sebetralstat). The finding comes from an interim analysis of data from the open-label extension (OLE) study,…
Kalvista Pharmaceuticals saw approximately $49 million in global revenue from Ekterly (sebetralstat) in the treatment’s initial six months on the market, according to a year-end update. Approved in mid-2025 as the first oral on-demand treatment for hereditary angioedema (HAE) in the U.S. and Europe, the therapy generated…
A rapid response to Ruconest (recombinant C1 esterase inhibitor) may support an otherwise difficult diagnosis of a rare form of hereditary angioedema (HAE) marked by normal levels of C1-inhibitor (C1-INH) protein, a study suggested. This form of the disease, HAE-nl-C1INH, is challenging to diagnose because there are…
Throughout 2025, the team at Angioedema News brought readers the latest updates on research, treatments, clinical trials, and real-world experiences related to angioedema. From progress in gene-editing approaches to insights into how patients manage swelling attacks, our goal has been to support people living with this rare condition…
Daily treatment with Orladeyo (berotralstat) oral granules led to early and sustained reductions in swelling attack rates in young children with hereditary angioedema (HAE), according to one-year interim data from an ongoing Phase 3 trial. The data, together with additional analyses on disease burden and patient experience, were presented…
Most people with hereditary angioedema (HAE) who received a single, 50 mg dose of lonvoguran ziclumeran, also called lonvo-z and formerly known as NTLA-2002, in a clinical trial have remained free from swelling attacks and no longer require long-term preventive therapy up to three years of follow-up. That’s according…
Note: This story was updated Dec. 15, 2025, to clarify the FDA approval covers a new oral pellet formulation of Orladeyo. The U.S. Food and Drug Administration (FDA) expanded the approval of Orladeyo (berotralstat), making it the only oral treatment approved in the U.S. as a prophylactic (preventive) therapy…
Suddenly stopping long-term preventive treatment with danazol — a hormone therapy being phased out in hereditary angioedema (HAE) — caused temporary hepatitis, or an inflammation of the liver, for five adults with HAE in the Netherlands, a new study found. According to the researchers, these findings suggest that…
On-demand treatment with deucrictibant can help resolve swelling attacks in people with all major forms of hereditary angioedema (HAE), according to top-line data from a Phase 3 clinical trial. Pharvaris, deucrictibant’s developer, plans to use the Phase 3 findings to support a U.S. Food and Drug Administration (FDA)…
Recent Posts
- Blood pressure medication causes rare life-threatening reaction after 11 years
- Rare HAE diagnosis explains years of severe abdominal pain in man
- I forget that my daughter with HAE can also face common illness
- Dawnzera reduces HAE attacks by over 80% over 4 years, per final study data
- It’s difficult to encounter people who don’t understand invisible disability